Since the original topiramate studies were performed a decade ago, it is unknown whether, or to what extent, the standard antiepileptic drugs are effective in modern-day treatment-resistant patients. Thus, equal improvement in both groups could represent an equal placebo effect in both arms. Moreover, many of the patients, although not currently receiving topiramate, may have failed it in the past, possibly handicapping the comparator. Selecting an appropriate dose and titration schedule would also be an issue.

As noted in our article, it is critical to understand the mode of use of a new drug, which commonly emerges during phase II and III clinical trials, before designing a comparative trial with a

standard drug. When it comes to new drug testing, we need to learn how to crawl before we can walk.

Jacqueline A. French, New York, NY; John D. England, New Orleans, LA

Disclosure: See original article for full disclosure list.

Copyright © 2011 by AAN Enterprises, Inc.

1. French JA, England JD. Comparative effectiveness research, evidence-based medicine, and the AAN. *Neurology* 2010;75:562–567.
2. Dorsey ER, Meltzer DO. The economics of comparative effectiveness research. *Neurology* 2010;75:492–493.
3. French JA, Costantini C, Brodsky A, von Rosenstiel P. Adjunctive brivaracetam for refractory partial-onset seizures. *Neurology* 2010;75:519–525.

CORRECTION

Decreased serum BDNF levels in patients with epileptic and psychogenic nonepileptic seizures

In the article “Decreased serum BDNF levels in patients with epileptic and psychogenic nonepileptic seizures” by W.C. LaFrance, Jr., et al. (*Neurology*® 2010;75:1285–1291), the authors found that patient samples were collected in lavender-top EDTA plasma tubes, rather than red-top serum tubes. The authors reviewed the literature^{1–4} to examine whether this would impact the findings and concluded that use of plasma does not compromise the results. For more accurate reporting and for any attempt to replicate the experiment, all references in the article to “serum BDNF” should read: “plasma BDNF.” The authors regret the error.

REFERENCES

1. Research Based Medicine. Comparison of Serum to Three Plasma Anticoagulant Samples (EDTA, Citrate and Heparin) Using the Human MAP. Austin, TX: Rules Based Medicine; Web site accessed December 5, 2010.
2. BDNF EMax ImmunoAssay System Technical Bulletin. Madison, WI: Promega Corporation; 2009.
3. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. *World J Biol Psychiatry* 2010;11:763–773.
4. Marano CM, Phatak P, Vemulapalli UR, et al. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. *J Clin Psychiatry* 2007;68:512–517.

Neurology®

Decreased serum BDNF levels in patients with epileptic and psychogenic nonepileptic seizures

Neurology 2011;76;935

DOI 10.1212/WNL.0b013e31820e44fb

This information is current as of March 7, 2011

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/76/10/935.full>

References

This article cites 2 articles, 0 of which you can access for free at:
<http://n.neurology.org/content/76/10/935.full#ref-list-1>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2011 by AAN Enterprises, Inc.. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.